Nano-co-delivery of lipophosphoglycan with soluble and autoclaved leishmania antigens into PLGA nanoparticles: Evaluation of in vitro and in vivo immunostimulatory effects against visceral leishmaniasis

Tosyali, Ozlem Ayse; Allahverdiyev, Adil M.; Bağırova, Melahat; Abamor, Emrah Şefik; Aydoğdu, Mehmet Onur; Dinparvar, Sahar; Acar, Tayfun; Mustafaeva, Zeynep; Derman, Serap

doi:10.1016/j.msec.2020.111684

Cited by 34 publications

(20 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The parasitological data revealed that only the LAPSmP and LAPSmG groups were able to reduce the parasite load in both liver and spleen, demonstrating a notable capacity in controlling parasite spread in hamsters. Similarly, corroborating the potential of the application of nanoparticles for vaccines against VL, other studies also reported a reduction in the L. infantum parasite load in in-fected and vaccinated animals [26,27,28,52,61]. In agreement with these findings, no correlation was observed between the parasite load and antibody production in these vaccinated groups, despite the elevated levels of IgG produced by the LAPSmP and LAPSmG groups.…”

Section: Discussionsupporting

confidence: 70%

Vaccination with Formulation of Nanoparticles Loaded with Leishmania amazonensis Antigens Confers Protection against Experimental Visceral Leishmaniasis in Hamster

González¹,

Gonçalves²,

Ottino³

et al. 2022

Preprint

View full text Add to dashboard Cite

Visceral leishmaniasis (VL)is a fatal disease caused by the protozoa Leishmania infantum for which dogs are the main reservoirs. A vaccine against canine visceral leishmaniasis (CVL) could be an important tool in the control of human and CVL by reducing the infection pressure of L. infantum. Despite the CVL vaccine available on the market, the Brazilian Ministry of Health did not implement the use of it in their control programs. In this sense, there is an urgent need to develop more efficient vaccines. In this study, the association between two polymeric nanoformulations, [poly (D, L-lactic) acid (PLA) polymer] loading Leishmania amazonensis antigens, was evaluated as a potential immunobiological agent against VL using golden hamsters as an experimental model. The results indicated that no significant adverse reactions were observed in animals vaccinated with LAPSmP. LAPSmP presented similar levels of total anti-Leishmania IgG as compared to LAPSmG. The LAPSmP and LAPSmG groups showed an intense reduction in liver and spleen parasitic load by qPCR. The LAPSmP and LAPSmG vaccines showed exceptional results, indicating that they may be promising candidates as a VL vaccine.

show abstract

Section: Discussionsupporting

confidence: 70%

Vaccination with Formulation of Nanoparticles Loaded with Leishmania amazonensis Antigens Confers Protection against Experimental Visceral Leishmaniasis in Hamster

González¹,

Gonçalves²,

Ottino³

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…Recently Tosyali OA, et al, 2021 prepared a nano-co-delivery of lipophosphoglycan with soluble and autoclaved leishmania antigens into PLGA nanoparticles vaccine formulations by encapsulation of SLA-LPG and ALA-LPG dual antigens, characterize synthetized nanoparticles with different methods and evaluate their in vitro and in vivo immunostimulatory activities against visceral leishmaniasis and examining vaccine efficacies of PLGA nanoparticles carrying dual Leishmania antigens. PLGA nanoparticles by this method also improved the humoral and cellular immune responses without leading to any side effects, no toxicity against macrophages and produce nitric oxide and cytokines, and reduced the parasite burdens in murine visceral organs following to infection challenge [133].…”

Section: Design Of Experiments (Doe) and Design Spacementioning

confidence: 96%

Quality by design prospects of pharmaceuticals application of double emulsion method for PLGA loaded nanoparticles

et al. 2021

View full text Add to dashboard Cite

QbD approach empowers the pharma researchers to minimize the number of experimental trials and time. It helps identify the significant, influential factors such as critical material attributes, critical formulation variables, and critical process parameters, which may significantly impact the quality of the products. Poly lactic-co-glycolic acid (PLGA), a biocompatible and biodegradable polymer, has gained an immense potential and wide range of applications as a carrier for manufacturing of polymeric nanoparticle drug delivery systems as per US-FDA and European Medicine Agency for drug delivery. The double emulsion method for preparing PLGA nanoparticles to encapsulate hydrophilic drugs has attracted interest in manufacturing processes. The double emulsion is a two-step process consisting of two different emulsification, making the process more complicated. The stability of nanoparticles obtained by a double emulsion method remains questionable due to the many formulations and process attributes. Currently, PLGA based nanoparticles prepared by a double emulsion technique are an alternative pharmaceutical manufacturing operation for getting the quality product by employing the Quality by Design approach. This present review has discussed the QbD elements to elucidate the effect of material attributes, formulation, and process variables on the critical quality attributes of the drug product, such as particle size distribution, encapsulation efficiency, etc. The components of a double emulsion, characteristics of drugs, polymers, and stabilizers used have been discussed in detail in this review. Graphic abstract

show abstract

“…The combined signals provided by the parasitized macrophages displaying Leishmania antigenic epitopes and their interaction with naïve CD4 + T cells bearing cognate T cell receptors lead to the development of an antigen-specific effector T-cell response. Accordingly, the role of macrophages in Leishmania clearance during challenge infection following activation of T effector cells has been reported in numerous experimental vaccines including protein-based, nano-particulate encapsulated, and DNA-based vaccines (143)(144)(145)(146)(147). The macrophage chemokine network is critical in producing tissue resident CD4+T memory cells (TRM) in viral vaccines (148).…”

Section: Role Of Macrophages In Vaccine Induced Immunitymentioning

confidence: 99%

Determinants of Innate Immunity in Visceral Leishmaniasis and Their Implication in Vaccine Development

et al. 2021

View full text Add to dashboard Cite

Leishmaniasis is endemic to the tropical and subtropical regions of the world and is transmitted by the bite of an infected sand fly. The multifaceted interactions between Leishmania, the host innate immune cells, and the adaptive immunity determine the severity of pathogenesis and disease development. Leishmania parasites establish a chronic infection by subversion and attenuation of the microbicidal functions of phagocytic innate immune cells such as neutrophils, macrophages and dendritic cells (DCs). Other innate cells such as inflammatory monocytes, mast cells and NK cells, also contribute to resistance and/or susceptibility to Leishmania infection. In addition to the cytokine/chemokine signals from the innate immune cells, recent studies identified the subtle shifts in the metabolic pathways of the innate cells that activate distinct immune signal cascades. The nexus between metabolic pathways, epigenetic reprogramming and the immune signaling cascades that drive the divergent innate immune responses, remains to be fully understood in Leishmania pathogenesis. Further, development of safe and efficacious vaccines against Leishmaniasis requires a broader understanding of the early interactions between the parasites and innate immune cells. In this review we focus on the current understanding of the specific role of innate immune cells, the metabolomic and epigenetic reprogramming and immune regulation that occurs during visceral leishmaniasis, and the strategies used by the parasite to evade and modulate host immunity. We highlight how such pathways could be exploited in the development of safe and efficacious Leishmania vaccines.

show abstract

Nano-co-delivery of lipophosphoglycan with soluble and autoclaved leishmania antigens into PLGA nanoparticles: Evaluation of in vitro and in vivo immunostimulatory effects against visceral leishmaniasis

Cited by 34 publications

References 48 publications

Vaccination with Formulation of Nanoparticles Loaded with <em>Leishmania</em> <em>amazonensis</em> Antigens Confers Protection against Experimental Visceral Leishmaniasis in Hamster

Vaccination with Formulation of Nanoparticles Loaded with <em>Leishmania</em> <em>amazonensis</em> Antigens Confers Protection against Experimental Visceral Leishmaniasis in Hamster

Quality by design prospects of pharmaceuticals application of double emulsion method for PLGA loaded nanoparticles

Determinants of Innate Immunity in Visceral Leishmaniasis and Their Implication in Vaccine Development

Contact Info

Product

Resources

About